NNLX's public updates are replete with references
Post# of 9144
(Total Views: 510)
Posted On: 06/26/2019 2:44:40 PM
NNLX's public updates are replete with references to partnering with the big boys
and my posts abundantly describe the processes and the difficulties in doing so-difficulties shared essentially by all small companies in negotiating with a much larger entity
NNLX has also partnered with govt agencies in the past and participated with several large entities in the Africa TB initiatives,which included the Bill and Melinda Gates foundation
plus, as we have reported since July 2017 NNLX has gone to a lot of work in attempting to partner with entities in europe and elsewhere, as they have described in their updates
as noted in an update I repost here, the identity of the California biotech company will be revealed "once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge"
This is all in the "board information" section for easy reference
Posted On: 04/02/2019 12:44:58 PM
Posted By: Kachingpdx1
Update on N-Assay
Overview and Potential in Multi-billion Diagnostics Market
NanoLogix is pleased to add an important PowerPoint Presentation update to our January 2019 statement of coordinated bacteria pretest development activity with two Biotechnology firms .
The PowerPoint Presentation can be viewed on The NanoLogix website at: http://nanologix.com/
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
Further updates will occur as warranted.
Update on N-Assay Pretest Development 1-16-19 posted by Eudius
NIH Grant Application Submitted for
Pre-test Development Study
NanoLogix is pleased to provide this update to our August 2018 statement of coordinated development activity with a California-based Biotechnology firm . The planning for a research study for development of a rapid pre-test for use with the patented Nanologix N-Assay bacteria diagnostic is proceeding, with staff selections completed, letters of recommendation from noted medical authorities written, and the submission last week of the grant application for the study to the NIH by our Silicon-Valley partner . The research study is planned for two major Houston hospitals, funded from both Federal Grants and a raise of investment capital.
The personnel agreeing to participate in the study are seven MDs, two research nurses, two microbiologists, at least two laboratory technicians, and the CEO of the California Biotechnology company. NanoLogix personnel and the CEO of the Biotechnology company have signed a mutual non-disclosure agreement limiting what can presently be revealed but once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge.
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required. This development will significantly reduce reliance upon broad-spectrum antibiotics, which contribute to the major worldwide problem of the development of antibiotic-resistance for many bacteria.
The current focus of this NIH grant application is on Group B Streptoccus (GBS). We are currently discussng Urinary Tract Infection (UTI) diagnostic test development with other companies and plan to proceed concurrently with studies for that development.
NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.
Although our partner has a very successful record of receiving grants for development, neither NanoLogix nor our partner in the GBS pretest development can guarantee that the NIH grant will be awarded for this project. With that in mind, nanoLogix is continuing to pursue alternative funding for both the GBS and UTI pretest development, including international sale or licensing of the FlatPack extended-life petri plate packaging technology.
Further updates will occur as warranted.
and my posts abundantly describe the processes and the difficulties in doing so-difficulties shared essentially by all small companies in negotiating with a much larger entity
NNLX has also partnered with govt agencies in the past and participated with several large entities in the Africa TB initiatives,which included the Bill and Melinda Gates foundation
plus, as we have reported since July 2017 NNLX has gone to a lot of work in attempting to partner with entities in europe and elsewhere, as they have described in their updates
as noted in an update I repost here, the identity of the California biotech company will be revealed "once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge"
This is all in the "board information" section for easy reference
Posted On: 04/02/2019 12:44:58 PM
Posted By: Kachingpdx1
Update on N-Assay
Overview and Potential in Multi-billion Diagnostics Market
NanoLogix is pleased to add an important PowerPoint Presentation update to our January 2019 statement of coordinated bacteria pretest development activity with two Biotechnology firms .
The PowerPoint Presentation can be viewed on The NanoLogix website at: http://nanologix.com/
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
Further updates will occur as warranted.
Update on N-Assay Pretest Development 1-16-19 posted by Eudius
NIH Grant Application Submitted for
Pre-test Development Study
NanoLogix is pleased to provide this update to our August 2018 statement of coordinated development activity with a California-based Biotechnology firm . The planning for a research study for development of a rapid pre-test for use with the patented Nanologix N-Assay bacteria diagnostic is proceeding, with staff selections completed, letters of recommendation from noted medical authorities written, and the submission last week of the grant application for the study to the NIH by our Silicon-Valley partner . The research study is planned for two major Houston hospitals, funded from both Federal Grants and a raise of investment capital.
The personnel agreeing to participate in the study are seven MDs, two research nurses, two microbiologists, at least two laboratory technicians, and the CEO of the California Biotechnology company. NanoLogix personnel and the CEO of the Biotechnology company have signed a mutual non-disclosure agreement limiting what can presently be revealed but once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge.
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required. This development will significantly reduce reliance upon broad-spectrum antibiotics, which contribute to the major worldwide problem of the development of antibiotic-resistance for many bacteria.
The current focus of this NIH grant application is on Group B Streptoccus (GBS). We are currently discussng Urinary Tract Infection (UTI) diagnostic test development with other companies and plan to proceed concurrently with studies for that development.
NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.
Although our partner has a very successful record of receiving grants for development, neither NanoLogix nor our partner in the GBS pretest development can guarantee that the NIH grant will be awarded for this project. With that in mind, nanoLogix is continuing to pursue alternative funding for both the GBS and UTI pretest development, including international sale or licensing of the FlatPack extended-life petri plate packaging technology.
Further updates will occur as warranted.
(4)
(0)